Source comparison
Comparison: CJC-1295 (no DAC) vs. CJC-1295 (with DAC)
Understanding the differences between the two primary forms of CJC-1295 is critical for any researcher following [CJC-1295 clinical trials 2026]. Both are GHRH analogs, but their pharmacokinetic profiles diverge significantly due to the presence of the Drug Af
This comparison does not assign a generated winner or score.
- Understanding the differences between the two primary forms of CJC-1295 is critical for any researcher following [CJC-1295 clinical trials 2026]. Both are GHRH analogs, but their pharmacokinetic profiles diverge significantly due to the presence of the Drug Affinity Complex (DAC) modification. This distinction influences research protocols, half-life, and ultimately, the interpretation of results.
- Half-Life
- Short (approx. 30 minutes)
- Long (approx. 6-8 days)
- Mechanism
- Binds to GHRH receptors; rapid clearance
- Binds to albumin; slow release, sustained effect
- Dosing Frequency
- Multiple times per day in research typically
- Once or twice a week in research typically
- GH Pulsatility
- Preserves more natural, frequent GH pulses
- Sustains elevated GH levels more consistently
- Research Use Cases
- Acute GH stimulation, precise timing studies
- Long-term studies, sustained GH elevation
- Availability at Real Peptides
- CJC 1295 (no Dac)
- Often found in blended products like CJC-1295 + Ipamorelin (5mg/5mg)
- This table illustrates why selecting the correct variant is crucial for aligning with specific research objectives gleaned from [CJC-1295 clinical trials 2026]. We've found that each form offers unique advantages depending on the desired experimental outcome, whether it's a study requiring frequent, physiological-like pulses of GH or one benefiting from sustained, stable levels over a longer period. Our dedication to quality extends across our full range of peptides, ensuring you have the precise tools for your lab.